Price
$0.5259
Decreased by -16.52%
Dollar Volume
148.79 K
ADR%
12.82
Earnings Report Date (estimate)
Nov 14, 22 (N/A)
Market Cap.
52.18 M
Shares Float
37.78 M
Shares Outstanding
99.22 M
Beta
0.81
Price / Earnings
-5.16
BPR
10.34
20D Range
0.38 0.75
50D Range
0.38 0.79
200D Range
0.38 0.94
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 317.39 K
Decreased by -34.80%
-5.41 M
Decreased by -167.47%
Decreased by -1.71 K%
Decreased by -310.20%
Jun 30, 22 290.82 K
Increased by +3.78%
-2.03 M
Increased by +14.23%
Decreased by -697.50%
Increased by +17.35%
Mar 31, 22 297.63 K
Increased by +2.71%
-2.07 M
Increased by +12.53%
Decreased by -695.67%
Increased by +14.84%
Dec 31, 21 334.20 K
Decreased by -26.48%
-2.33 M
Decreased by -75.19 K%
Decreased by -698.46%
Decreased by -102.30 K%
Sep 30, 21 486.76 K
Increased by +49.78%
-2.02 M
Increased by +37.75%
Decreased by -415.85%
Increased by +58.44%
Jun 30, 21 280.23 K
Decreased by -6.98%
-2.36 M
Increased by +22.62%
Decreased by -843.91%
Increased by +16.82%
Mar 31, 21 289.77 K
Decreased by -2.42%
-2.37 M
Increased by +27.63%
Decreased by -816.88%
Increased by +25.83%
Dec 31, 20 454.56 K
Decreased by -5.14%
-3.10 K
Increased by +99.94%
Decreased by -0.68%
Increased by +99.94%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.